Ccr1 (NM_009912) Mouse Tagged ORF Clone Lentiviral Particle

CAT#: MR205412L4V

  • LentiORF®

Lenti ORF particles, Ccr1 (GFP-tagged) - Mouse chemokine (C-C motif) receptor 1 (Ccr1), 200ul, >10^7 TU/mL

ORF Plasmid: DDK tGFP



Need custom lentivirus service?
Get a free quote

CNY 8,360.00


货期*
详询

规格
    • 200 ul

Product images

经常一起买 (3)
Lenti ORF control particles of pLenti-C-mGFP-P2A-Puro, >1x10^7 TU/ml, 0.5 ml
    • 500 ul

CNY 2,950.00


One-Wash Lentivirus Titer Kit, HIV-1 p24 ELISA
    • 96 reactions

CNY 5,230.00


CCR1 Antibody - middle region
    • 50 ug

CNY 4,628.00

Specifications

Product Data
Product Name Ccr1 (NM_009912) Mouse Tagged ORF Clone Lentiviral Particle
Synonyms Cmkbr1; Mip-1a-R
Vector pLenti-C-mGFP-P2A-Puro
ACCN NM_009912
ORF Size 1065 bp
Sequence Data
The ORF insert of this clone is exactly the same as(MR205412).
OTI Disclaimer The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
OTI Annotation This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
Reference Data
RefSeq NM_009912.2
RefSeq Size 2708 bp
RefSeq ORF 1068 bp
Locus ID 12768
Gene Summary Receptor for a C-C type chemokine. Binds to MIP-1-alpha, RANTES, and less efficiently, to MIP-1-beta or MCP-1 and subsequently transduces a signal by increasing the intracellular calcium ions level. Responsible for affecting stem cell proliferation.[UniProtKB/Swiss-Prot Function]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...